Plant Name: Citrus maxima
Taxonomic Information:
Plant ID: NPO27288
Plant Latin Name: Citrus maxima
Taxonomy Genus: Citrus
Taxonomy Family: Rutaceae
Plant External Links:
NCBI TaxonomyDB:
37334
Plant-of-the-World-Online:
30075266-2
Used in Medicines:
Country/Region:
Philippines; IndiaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Ayurveda; SiddhaGeographical Distribution:
Jamaica; Bangladesh; Myanmar; Cuba; Gambia; Philippines; Indonesia; India; Cambodia; Trinidad and Tobago; Vietnam; China; Thailand; Dominican Republic; Bolivia; Fiji; Haiti; Ecuador
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ACHE; | |
| RECQL; FAAH; HSD17B1; HSD17B2; HSD17B10; ALOX15; POLB; | |
| TRPV1; | |
| CSNK2A1; | |
| CA2; CA12; CA9; CA14; CA7; CA4; | |
| PPARA; | |
| RORC; | |
| THRB; | |
| NR1H4; | |
| ESR2; | |
| TYR; | |
| MMP9; MMP1; MMP2; | |
| AHR; TP53; NFKB1; | |
| LMNA; FABP4; FABP5; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.629E-13 | 1.908E-09 | CA12, CA14, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.019E-12 | 1.750E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.348E-12 | 2.667E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.357E-10 | 3.422E-07 | CYP1A2, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.549E-10 | 4.546E-07 | CA12, CA14, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.103E-10 | 4.963E-07 | CA12, CA2, CA4, CA7, CA9, ESR2, MMP1, MMP2, MMP9, NR1H4, PPARA, RORC, THRB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.836E-10 | 6.354E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.621E-10 | 8.057E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.141E-09 | 9.206E-07 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 7.393E-09 | 4.766E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.825E-09 | 4.868E-06 | CYP19A1, CYP1A1, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.057E-08 | 6.393E-06 | CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.356E-07 | 6.417E-05 | ESR2, NR1H4, PPARA, RORC, THRB |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.583E-07 | 7.045E-05 | CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, HSD17B2, NFKB1, NR1H4, RORC, TP53, TYR |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 1.697E-07 | 7.245E-05 | CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, NFKB1, RORC, TP53, TRPV1, TYR |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.509E-06 | 5.299E-04 | AHR, ESR2, NR1H4, PPARA, RORC, THRB |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.787E-06 | 6.079E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.787E-06 | 6.079E-04 | CYP1A2, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.319E-06 | 7.652E-04 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 6.962E-06 | 2.021E-03 | ESR2, NR1H4, PPARA, RORC, THRB |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.066E-05 | 2.902E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.253E-05 | 3.368E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.416E-05 | 3.714E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0016042; lipid catabolic process | 1.817E-05 | 4.655E-03 | CYP19A1, CYP1A2, CYP1B1, FAAH, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.907E-05 | 4.773E-03 | ESR2, NR1H4, PPARA, RORC, THRB |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.502E-05 | 5.796E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.502E-05 | 5.796E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.962E-05 | 6.261E-03 | ESR2, HSD17B1, NR1H4, RORC |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 3.269E-05 | 6.845E-03 | ACHE, ALOX15, CYP1A1, PPARA, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.263E-13 | 6.053E-11 | CA12, CA2, CA4, CA7, CA9, CA14 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.621E-09 | 9.323E-08 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.898E-08 | 1.878E-06 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.358E-07 | 7.723E-06 | CYP2C9, CYP2D6, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.142E-07 | 7.723E-06 | CYP2C9, CYP1A2, ALOX15, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.020E-07 | 1.154E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.317E-06 | 2.163E-05 | MMP1, MMP2, MMP9, TP53 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.080E-05 | 1.379E-04 | CYP2C9, CYP2D6, CYP1A2, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.080E-05 | 1.379E-04 | FABP4, FABP5, MMP1, PPARA |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.230E-04 | 1.179E-03 | CYP2C9, HSD17B1, HSD17B2, CYP1A2, ALOX15, CYP1A1, CYP2C19, TYR, CYP19A1, HSD17B10 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 7.290E-05 | 7.622E-04 | CYP2C9, CYP2D6, ALOX15, CYP2C19 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 6.956E-05 | 7.622E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.583E-04 | 2.285E-03 | CYP2C9, ALOX15, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.116E-03 | 7.552E-03 | MMP1, MMP2, TP53, MMP9, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.971E-04 | 2.440E-03 | CYP2C9, CYP1A2, CYP1A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.018E-03 | 7.315E-03 | MMP2, MMP9, ESR2 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 9.609E-04 | 7.315E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; TYR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| NA: NA | Edema | NA | CA2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; TP53; MMP2; CA9; |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | TRPV1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; NFKB1; ACHE; MMP9; TP53; MMP2; CA9; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | FAAH; ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH; ACHE; TRPV1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | THRB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| NA: NA | Esophagus sensitivity | NA | TRPV1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
